Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: Will Roche be the last to know?

This article was originally published in Scrip

Executive Summary

In late 2000 when I was a fresh-faced investor just out of the anti-infectives group at SmithKline Beecham (SB), a colleague took me up to Manchester to see one of 3i's then private investments called NeuTec Pharma. During the meeting I had to point out that NeuTec's estimates for its lead product were 95% too high because they were mistakenly based on the largest instead of the smallest variant of the product that I had been managing at SB until a few months earlier. Imagine my surprise a few years later – after NeuTec's IPO and after 3i had divested its holding because NeuTec's products were all still un-partnered – when Novartis (which our fund owns) acquired NeuTec for $305m (scripintelligence.com, 09 June 2006).

You may also be interested in...



Stockwatch: The Victimization Of Big Biotech

Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.

Stockwatch: Reading The Entrails Of Biotech Vaccine Development

As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.

Stockwatch: Coronavirus Impacts At Generic Pharmaceuticals – A Mixed Bag

Following Mylan’s first-quarter 2020 earnings announcement, all the biggest generic pharmaceutical companies have now reported. Concerns about supply chain disruptions in March have proven to have been overblown and guidance has largely been reaffirmed. So, are generics immune from coronavirus?

Topics

Related Companies

UsernamePublicRestriction

Register

SC142288

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel